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GSK3 is a negative regulator of the 
thermogenic program in brown 
adipocytes
Lasse K. Markussen1, Sally Winther1, Barton Wicksteed2 & Jacob B. Hansen  1
Brown adipose tissue is a promising therapeutic target in metabolic disorders due to its ability to 
dissipate energy and improve systemic insulin sensitivity and glucose homeostasis. β-Adrenergic 
stimulation of brown adipocytes leads to an increase in oxygen consumption and induction of a 
thermogenic gene program that includes uncoupling protein 1 (Ucp1) and fibroblast growth factor 21 
(Fgf21). In kinase inhibitor screens, we have identified glycogen synthase kinase 3 (GSK3) as a negative 
regulator of basal and β-adrenergically stimulated Fgf21 expression in cultured brown adipocytes. 
In addition, inhibition of GSK3 also caused increased Ucp1 expression and oxygen consumption. 
β-Adrenergic stimulation triggered an inhibitory phosphorylation of GSK3 in a protein kinase A (PKA)-
dependent manner. Mechanistically, inhibition of GSK3 activated the mitogen activated protein kinase 
(MAPK) kinase 3/6-p38 MAPK-activating transcription factor 2 signaling module. In summary, our data 
describe GSK3 as a novel negative regulator of β-adrenergic signaling in brown adipocytes.
The discovery of active brown adipose tissue (BAT) in healthy adults has revitalized the concept of combating 
metabolic dysfunction via recruitment and activation of brown adipocytes1–3. BAT can dissipate energy by uncou-
pled respiration, a process called adaptive thermogenesis1–3. BAT is classically activated by cold, which through 
sympathetic nervous system-mediated release of norepinephrine at the surface of brown adipocytes activates 
β-adrenergic receptors. This activation results in augmented lipolysis, mitochondrial uncoupling, oxygen con-
sumption and thermogenesis. In mice, activated BAT promotes glucose and triacylglycerol clearance, improves 
insulin sensitivity and glucose tolerance, and counteracts obesity1–3. Most of these effects of brown adipocytes 
depend on their high mitochondrial density, the unique presence of uncoupling protein 1 (UCP1) in the inner 
mitochondrial membrane and a high oxidative capacity1–3. In humans, BAT activity correlates with cold-induced 
energy expenditure and BAT activity is recruited after regular cold exposures4,5. In addition, brown-like (also 
called beige, brite or inducible brown) adipocytes appear in certain white adipose tissues in response to prolonged 
cold exposure or treatment with β-adrenergic agonists1–3.
Recent data suggest that BAT has beneficial metabolic functions beyond thermogenesis which might involve 
an endocrine role6,7. Several signaling molecules with hormonal properties have been found to be released by 
BAT, particularly under conditions of cold-induced BAT activation7. Additionally, the improved glucose toler-
ance, enhanced insulin sensitivity and decreased adiposity observed with BAT transplantation have also been 
associated with the endocrine properties of BAT8,9. Recent reports have established fibroblast growth factor 21 
(FGF21) as a bona fide BAT-released factor, secreted by brown adipocytes following cold or β-adrenergic stim-
ulation10–12. Fgf21 expression is controlled by activating transcription factor 2 (ATF2), which in turn is acti-
vated by β-adrenergic stimulation in a cAMP-protein kinase A (PKA)-mitogen activated protein kinase (MAPK) 
kinase 3/6 (MKK3/6)-p38 MAPK-dependent manner10. The same intracellular signaling pathway that controls 
Fgf21 expression in brown adipocytes is required for induction of a broader thermogenic gene expression pro-
gram that also includes uncoupling protein 1 (Ucp1), type II iodothyronine deiodinase (Dio2) and peroxisome 
proliferator-activated receptor γ co-activator-1α (Ppargc1α)10,13–16. Pharmacological administration of FGF21 has 
been ascribed a number of beneficial metabolic effects, including lowering of adiposity and increased glucose tol-
erance, and some of these effects have been associated with a direct effect of FGF21 on adipocytes17–19. Recently, 
autocrine and/or endocrine actions of FGF21 were shown to induce BAT differentiation and WAT browning 
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in response to activation of G protein-coupled receptor 12020. Glycogen synthase kinase 3 (GSK3) is a Ser/Thr 
kinase implicated in the insulin signaling pathway to control glycogen metabolism, but is now also recognized 
as a multifunctional kinase regulating an array of additional cellular functions21. GSK3 exists as two paralogs: 
GSK3α and GSK3β. Small-molecule inhibitors of GSK3 have favourable metabolic effects in rodents, including 
prevention of diet-induced obesity and improved glucose tolerance22–25. Thus, GSK3 inhibitors exert some of the 
same metabolic effects as FGF21 administration.
In a search for novel kinases regulating the thermogenic program of brown adipocytes, we carried out screens 
with a kinase inhibitor library. We identified GSK3 to be a novel negative regulator of Fgf21 and thermogenic gene 
expression in brown adipocytes. Following thermogenic activation, GSK3 becomes inactivated by phosphoryla-
tion in a PKA-dependent manner, which in turn leads to increased activity of the MKK3/6-p38 MAPK-ATF2 sig-
naling module. Thus, inhibition of GSK3 unleashes thermogenic signaling in brown adipocytes, an observation 
pointing to GSK3 as a potentially interesting target in metabolic diseases.
Results
FGF21 is under β-adrenergic control in adipose tissue and cultured brown adipocytes. Unbiased 
kinase inhibitor screens have been applied to successfully identify novel roles for kinases in regulating the for-
mation and function of thermogenic adipocytes26–28. Here we aimed to identify novel kinase functions involved 
in the β-adrenergically induced thermogenic gene program in brown adipocytes. To this end we decided to use 
Fgf21 mRNA levels as a read-out due to its reported high inducibility in BAT upon cold exposure and brown 
adipocytes in response to β-adrenergic stimulation10. Before searching for the involvement of novel kinases, we 
wanted to confirm Fgf21 as a meaningful read-out in our screens. Gene expression was measured by reverse tran-
scription-quantitative PCR (RT-qPCR).
First, we exposed mice to cold or thermoneutrality for 4 days. Cold exposure led to a significant induction of 
Ucp1 mRNA levels in interscapular and axillary BAT (iBAT and aBAT, respectively) and in the browning-prone 
inguinal WAT (iWAT) (Fig. 1a). Ucp1 was barely expressed in epididymal WAT (eWAT) and liver, irrespective 
of housing temperature. In line with previous reports10–12, we found that cold exposure strongly increased 
Fgf21 expression in thermogenesis-capable adipose tissue depots (BAT and iWAT) and only to a smaller extent 
in eWAT (Fig. 1b). Fgf21 expression was high in the liver but did not change with cold exposure. Beside 
transcriptional changes, cold exposure was associated with a decreased average body weight gain (Fig. 1c), a 
decreased iWAT mass (Fig. 1d) and an increased iBAT mass (Fig. 1e). However, we did not find the plasma 
concentration of FGF21 to be significantly altered by the cold exposure (Fig. 1f) despite the enhanced expres-
sion in adipose tissues.
Figure 1. FGF21 expression and secretion is under β-adrenergic control in brown adipocytes. Ten weeks old 
male C57BL/6JBomTac mice were housed at 29 °C (thermoneutrality, TN) or 4 °C (cold) for 4 days. Relative 
mRNA levels of Ucp1 (a) and Fgf21 (b) in various tissues. Cold exposure effect on average body weight gain 
during the 4-day period (c), iWAT wet weight (d) iBAT wet weight (e) and plasma concentration of FGF21 
(f). (g) Expression of Fgf21 in immortalized or primary brown adipocytes treated with 0.1 μM isoproterenol 
(ISO) for 6 h. (h) Secreted FGF21 in cell culture medium from immortalized or primary brown adipocytes 
treated with 0.1 μM ISO for 24 h. Data represent mean +SEM (n = 6, mice) or mean of means +SEM (n = 3, cell 
culture). Unpaired two-tailed Student’s t-test was applied in all panels. *p < 0.05 versus TN/H2O control.
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Next, we determined Fgf21 expression in cultured immortalized and primary brown adipocytes in response 
to β-adrenergic stimulation. In both cell models, Fgf21 mRNA levels increased after 6 h of stimulation with the 
pan-β-adrenergic receptor agonist isoproterenol (ISO) (Fig. 1g), which also resulted in a significant increase in 
medium FGF21 (Fig. 1h).
Thus, in line with previous reports, we show that brown adipocytes induce Fgf21 expression and secretion 
following β-adrenergic stimulation in a cell-autonomous manner.
Kinase inhibitor screen identifies GSK3 as an inhibitor of Fgf21 expression and secretion in 
brown adipocytes. To identify novel kinases involved in the β-adrenergically stimulated expression of 
Fgf21 in brown adipocytes we carried out a screen with 90 different kinase inhibitors. Mature immortalized 
brown adipocytes were pre-treated with kinase inhibitor and stimulated with ISO. All samples have been nor-
malized to the ISO-stimulated control cells to depict changes in ISO-induced Fgf21 mRNA levels (Fig. 2a). The 
unstimulated control (without ISO; blue column) showed that ISO stimulation increased Fgf21 expression by 
~40 fold. Of notice, the majority of the kinase inhibitors potentiated the effect of ISO. Two broad-spectrum 
kinase inhibitors (red columns) served as positive controls and were found to largely block ISO-induced Fgf21 
induction. Two GSK3 inhibitors, SB415286 and SB216763, increased the β-adrenergically induced Fgf21 mRNA 
expression ~3-fold, placing them among the 10 inhibitors with the strongest potentiating effect. A third GSK3 
inhibitor, BIO, elicited a less pronounced potentiating effect on Fgf21 expression in the screen (~1.4-fold above 
ISO-stimulation alone). In dedicated GSK3 inhibitor experiments all three inhibitors were found to elevate both 
basal and ISO-induced expression of Fgf21 expression by ~2 fold (Fig. 2b). In these experiments, BIO was as 
potent as SB415286 and SB216763. Treatment with SB216763 also increased both basal and ISO-induced FGF21 
secretion into the cell culture medium (Fig. 2c). In addition to BAT, other key metabolic tissues such as liver, 
WAT and skeletal muscle also express Fgf2119. Interestingly, SB216763 only increased basal expression of Fgf21 in 
mouse and human white adipocyte cell models (3T3-L1 and hMADS), but not in different hepatocyte cell models 
or muscle cell lines (Supplementary Fig. 1), suggesting that GSK3 might be an adipocyte-selective regulator of 
FGF21.
To confirm the kinase inhibitor results by genetic means, retroviral vectors encoding constitutively active 
(S9A) or kinase dead (K85A) HA-tagged human GSK3β were expressed in immortalized brown pre-adipocytes 
(Fig. 2d). Overexpression of GSK3β mutants did not appear to affect differentiation as indicated by nor-
mal expression of adipose-specific markers fatty acid binding protein 4 (Fabp4), adiponectin (AdipoQ) and 
CCAAT/enhancer binding protein α (Cebpα) (Fig. 2e). Constitutively active GSK3β decreased both basal and 
ISO-induced Fgf21 expression. The kinase dead mutant had a modest non-significant effect on the basal expres-
sion, but increased ISO-induced Fgf21 expression ~2–3 fold (Fig. 2f). Taken together, we have identified GSK3 as 
an adipocyte-selective negative regulator of FGF21.
GSK3 is a negative regulator of the thermogenic gene program. Next, we wanted to investigate 
if the effect of GSK3 was specific to the Fgf21 gene, or if GSK3 might regulate a broader thermogenic gene pro-
gram in brown adipocytes. Therefore, we measured the effect of SB216763 on expression of the β-adrenergically 
induced thermogenic genes Ucp1, Dio2 and Ppargc1α, in addition to Fgf21, in primary brown adipocytes. In 
these cells, SB216763 augmented ISO-induced expression of Fgf21, Ucp1, Dio2 and Ppargc1α (Fig. 3a). Basal 
expression was also increased by SB216763 for Fgf21, Dio2 and Ppargc1α, but not for Ucp1. The increased Ucp1 
mRNA levels translated into an increase in ISO-induced UCP1 protein (Fig. 3b). Consistent with the effects of 
SB216763, simultaneous siRNA-mediated knockdown of both GSK3 paralogs in mature primary brown adipo-
cytes significantly induced the expression of Dio2 and Ppargc1α at both the basal and β-adrenergically induced 
level (Fig. 3c). Knockdown of GSK3 caused an increased expression of Fgf21 in response to ISO stimulation, but 
did not influence basal Fgf21 expression. There was no effect of GSK3 knockdown on expression of Ucp1 (Fig. 3c) 
even though GSK3α and GSK3β protein levels were both substantially reduced by the reverse GSK3 siRNA trans-
fection (Fig. 3d).
The effect on the broader thermogenic gene program prompted us to measure the impact of GSK3 on oxygen 
consumption. Knockdown of both GSK3 paralogs in mature primary brown adipocytes caused a ~30% higher 
ISO-induced oxygen consumption rate compared with control cells (Fig. 3e,g), while no significant effect was 
observed under basal conditions (Fig. 3f).
Overall, this indicates that reduction of GSK3 activity in primary brown adipocytes activates the thermogenic 
gene program and oxygen consumption in response to β-adrenergic stimulation, consistent with GSK3 being a 
negative regulator of brown adipocyte thermogenic function.
GSK3 is inactivated after cold exposure and β-adrenergic stimulation in a PKA-dependent manner. 
GSK3 is believed to be ubiquitously expressed29. Probing various metabolically active tissues such as BAT, WAT, 
liver, skeletal muscle and heart confirmed expression of both paralogs in all tissues, albeit at varying levels 
(Fig. 4a). GSK3 is thought to be constitutively active in most tissues under normal physiological conditions, and 
its activity is mainly regulated by post-translational phosphorylation of an inhibitory amino acid residue: Ser21 
in GSK3α and Ser9 in GSK3β21. Interestingly, iBAT from mice exposed to cold for 24 h showed a marked increase 
in the inhibitory phosphorylation of both GSK3α and GSK3β compared to mice housed at ambient temperature 
(Fig. 4b). This observation was mimicked in immortalized brown adipocytes, as ISO stimulation increased the 
inhibitory phosphorylation of both GSK3 paralogs (Fig. 4c). Thus, GSK3 becomes inactivated by phosphorylation 
in brown adipocytes in response to β-adrenergic stimulation.
The major transducer of the β-adrenergic signal in brown adipocytes is PKA30 and the amino acid sequence 
around Ser21 in GSK3α and Ser9 in GSK3β is a high probability PKA consensus phosphorylation sequence 
(Fig. 5a). In addition, GSK3 activity can be inhibited by PKA through phosphorylation of these serine residues 
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in HEK293 and NIH3T3 cells31. Pre-treatment of immortalized brown adipocytes with the PKA inhibitor H89 
before β-adrenergic stimulation blunted the ISO-induced phosphorylation of both GSKα and GSK3β (Fig. 5b). 
Stimulation with the PKA-specific activator 6-MB-cAMP mimicked the effect of ISO on Ser9-phosphorylation 
of GSK3β, and to a smaller extent on Ser21-phosphorylation of GSK3α. iBAT from mice expressing a constitu-
tively active mutant allele of the PKA catalytic subunit α specifically in adipose tissue (AdipoQ-caPKA mice)32,33 
revealed a hyperphosphorylated pattern of the PKA substrate hormone sensitive lipase (HSL) as well as of GSK3α 
and GSK3β compared with control mice (Fig. 5c). Treatment of immortalized brown adipocytes with SB216763 
Figure 2. GSK3 is a negative regulator of Fgf21 expression and secretion in brown adipocytes. (a) Kinase 
inhibitor screen to identify novel regulators of Fgf21 expression in response to β-adrenergic stimulation. Fgf21 
expression in mature immortalized brown adipocytes pre-treated with 10 μM kinase inhibitor for 1 h before 
stimulation with 0.1 μM ISO for an additional 6 h. Unstimulated (blue) and broad spectrum inhibitor-treated 
cells (red) serve as controls. Green columns show cells pre-treated with GSK3 inhibitors. (b) Fgf21 mRNA levels 
in mature immortalized brown adipocytes pre-treated with 10 μM of the GSK3 inhibitors SB415286, SB216763 
and BIO for 1 h before being stimulated with 0.1 μM ISO for additional 6 h. (c) Secreted FGF21 in cell culture 
medium from immortalized brown adipocytes pre-treated with 10 μM SB216763 for 1 h before stimulation with 
0.1 μM ISO for an additional 24 h. (d) Immunoblot against HA-tag and total GSK3β in immortalized brown 
adipocytes overexpressing constitutively active (CA) or kinase dead (KD) GSK3β or empty vector. TFIIB serves 
as loading control. Full-length blots/gels are presented in Supplementary Fig. 2. (e) Expression of differentiation 
markers (Fabp4, AdipoQ and Cebpα) in immortalized brown adipocytes after ectopic overexpression of GSK3β 
mutants. (f) Fgf21 expression in immortalized brown adipocytes overexpressing GSK3β mutants or empty 
vector. Mature adipocytes were treated with 0.1 μM ISO for 6 h. Data represents mean of means +SEM from 3 
independent experiments. Statistical significance was determined by two-way ANOVA with repeated measures 
and Tukey’s post hoc test for multiple comparisons. *p < 0.05 versus H2O. #p < 0.05 versus vehicle/vector 
control. No statistical tests were applied to panel a.
www.nature.com/scientificreports/
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Figure 3. GSK3 restricts the thermogenic program in brown adipocytes. (a) Expression of thermogenic genes 
(Fgf21, Ucp1, Dio2 and Ppargc1α) in primary brown adipocytes pre-treated with 10 μM SB216763 for 1 h before 
being stimulated with 0.1 μM ISO for an additional 6 h. (b) Immunoblot analysis of UCP1 in primary brown 
adipocytes pre-treated with 10 μM SB216763 for 1 h before being stimulated with 0.1 μM ISO for an additional 
24 h. TFIIB serves as loading control. (c) Expression of thermogenic genes (Fgf21, Ucp1, Dio2 and Ppargc1α) in 
siRNA-transfected primary brown adipocytes stimulated with 0.1 μM ISO for 6 h. (d) Immunoblot analysis of 
GSK3α and GSK3β in siRNA-transfected primary brown adipocytes stimulated with 0.1 μM ISO for 24 h. TFIIB 
serves as loading control. (e) Representative normalized Seahorse run of oxygen consumption rates (OCR) in 
siRNA-transfected primary brown adipocytes. Quantification of basal (f) and ISO (1 μM)-induced (g) OCR. 
RT-qPCR data are presented as mean of means (+SEM) (n = 4). Statistical significance was determined by 
two-way ANOVA with repeated measures and Tukey’s post hoc test for multiple comparisons. *p < 0.05 versus 
H2O. #p < 0.05 versus vehicle/scramble. Seahorse data are presented as mean (±SEM) of one representative 
experiment (e) or 3 independent experiments (f,g) and significance was determined by paired t-test (*p < 0.05). 
For panels b and d, full-length blots/gels are presented in Supplementary Fig. 2.
www.nature.com/scientificreports/
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did not result in increased basal or ISO-induced lipolysis (Fig. 5d) or altered phosphorylation status of major PKA 
target proteins (HSL, cAMP responsive element-binding protein (CREB) and PKA substrates detected with an 
anti-PKA substrate antibody) (Fig. 5e), suggesting that GSK3 does not interfere with PKA activity, but rather acts 
downstream of PKA in the β-adrenergic signaling pathway.
In summary, these data suggest that the inactivating phosphorylation of GSK3 in response to β-adrenergic 
stimulation is dependent on PKA activity in brown adipocytes.
Inhibition of GSK3 promotes activation of the MKK3/6-p38 MAPK-ATF2 signaling module. 
Activation of the thermogenic gene program has been shown to depend on the MKK3/6-p38 MAPK-ATF2 sig-
naling module that is activated downstream of PKA10,13–15. Treatment with SB216763 led to increased activat-
ing phosphorylations of MKK3/6, p38 MAPK and ATF2 in response to ISO stimulation (Fig. 6a). Moreover, 
SB216763 augmented the phosphorylation of p38 MAPK and ATF2 even in the absence of β-adrenergic stimu-
lation. These observations suggest that GSK3 activity normally inhibits this signaling module (Fig. 6a). Forced 
expression of a kinase dead version of GSK3β caused increased phosphorylation p38 MAPK in response to ISO, 
whereas a constitutively active GSK3β mutant blunted the normal ISO-induced p38 MAPK phosphorylation 
(Fig. 6b). Furthermore, the effect of SB216763 on both basal and β-adrenergically induced expression of Fgf21 
was abolished in cells pre-treated with the p38 MAPK inhibitor SB202190 (Fig. 6c). As expected, inhibition of 
p38 MAPK alone attenuated ISO-induced Fgf21 expression. Thus, these data demonstrate that GSK3 restricts p38 
MAPK signaling in brown adipocytes and that the effect of GSK3 inhibition depends on p38 MAPK activity. A 
schematic model of the proposed novel regulatory circuit of GSK3 inhibition of the MKK3/6-p38 MAPK-ATF2 
module in brown adipocytes is illustrated in Fig. 6d.
Discussion
In energy metabolism research, much effort is put into elucidating how to increase catabolic pathways, such as 
β-adrenergically induced thermogenesis in brown adipocytes. Here we show that under basal conditions, the 
expression of thermogenic genes in brown adipocytes is repressed through a GSK3-dependent inhibitory effect 
on the MKK3/6-p38 MAPK-ATF2 signaling module. Upon β-adrenergic stimulation, brown adipocytes partly 
release this repression on the thermogenic gene program through a PKA-dependent inactivation of GSK3 to 
expand the thermogenic transcriptional machinery, thereby forming a novel regulatory circuit.
GSK3 is known to be involved in glycogen storage and insulin signaling, but is now regarded as a multifunc-
tional kinase regulating an array of cellular functions21. In kinase inhibitor screens, we identified GSK3 as a negative 
Figure 4. Cold and β-adrenergic signaling cause inhibitory phosphorylation of GSK3 in brown adipocytes. 
(a) Immunoblot analysis of total GSK3α and GSK3β in various key metabolic tissues from 10 weeks old male 
C57BL/6JBomTac mice housed at room temperature; SKM (skeletal muscle). (b) Immunoblot analysis of total 
and phosphorylated GSK3α and GSK3β in iBAT from 10 weeks old male C57BL/6JBomTac mice housed at 
room temperature (RT) or 4 °C (cold) for 24 h. (c) Immunoblot analysis of total and phosphorylated GSK3α and 
GSK3β in immortalized brown adipocytes treated with 0.1 μM ISO for 1 h. Vinculin (tissues) or TFIIB (cells) 
serves as loading control. Full-length blots/gels are presented in Supplementary Fig. 2.
www.nature.com/scientificreports/
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regulator of the β-adrenergically stimulated increase in Fgf21 expression in mouse brown adipocytes (Fig. 2a). We 
confirmed the involvement of GSK3 by various approaches: chemical inhibitors, retroviral overexpression of mutant 
proteins, and siRNA-mediated knockdown. Inhibition of GSK3 by chemical inhibitors or depletion of GSK3 by 
siRNA was carried out in the mature adipocyte state, whereas retroviral transduction was performed in preadipo-
cytes. Even though GSK3 activity has been associated with adipogenesis in different adipocyte cell models (3T3-L1 
Figure 5. β-Adrenergic GSK3 inactivation is PKA dependent. (a) The PKA consensus sites around Ser21 
and Ser9 in GSK3α and GSK3β, respectively, are conserved in various species. (b) Immunoblot analysis of 
total and phosphorylated GSK3α and GSK3β in immortalized brown adipocytes treated with 40 μM H89 for 
1 h before stimulation with 0.1 μM ISO for additional 15 min. Some of the cells were stimulated with 100 μM 
6-MB-cAMP (6-MB) for 15 min. (c) Immunoblot analysis of total and phosphorylated GSK3α and GSK3β 
as well as phosphorylated HSL (Ser660) in iBAT from AdipoQ-caPKA and wild-type mice housed at room 
temperature. (d) Medium glycerol of immortalized brown adipocytes pre-treated with 10 μM SB216763 for 1 h 
before stimulation with 0.1 μM for 24 h. (e) Immunoblot analysis of phosphorylated and total HSL (Ser660), 
CREB (Ser133) and phosphorylated PKA substrates in immortalized brown adipocytes pre-treated with 10 μM 
SB216763 for 1 h before stimulation with 0.1 μM ISO for 1 h. Vinculin (tissues) or TFIIB (cells) serves as loading 
control. Data presented as mean of means +SEM (n = 4). Statistical significance was determined by two-way 
ANOVA with repeated measures and Tukey’s post hoc test for multiple comparisons. *p < 0.05 versus H2O, 
comparison between vehicle and SB216763 not significant (2d). For panels b, c and e, full-length blots/gels are 
presented in Supplementary Fig. 2.
www.nature.com/scientificreports/
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and hMADS)34–36, we observed no effect of the GSK3β mutants on adipocyte differentiation (Fig. 2e). This might be 
due to redundant effects of the two paralogs, where GSK3α was possibly able to sustain normal differentiation. Since 
forced expression of GSK3β mutants was sufficient to cause effects on Fgf21 expression, it is possible that the GSK3 
paralogs do not exert redundant effects on controlling Fgf21 levels. Non-redundant effects of the paralogs have been 
described, e.g. the GSK3β-regulated control of mitochondrial elongation induced by PKA signaling37. The catalytic 
domains of GSK3α and GSK3β are very similar but they differ in their C- and N-terminal regions21. However, from 
our results, we are unable to conclude on the relative contribution of each GSK3 paralog.
When analysing other thermogenic genes, we found that GSK3 was not just a regulator of Fgf21 expression, but 
had a broader effect on β-adrenergically stimulated gene transcription (Fig. 6a,b). Similar to Fgf21, Dio2 and Ppargc1α 
expression was increased with GSK3 inhibition or knockdown, both basally and following stimulation. Ucp1 expression 
was augmented following β-adrenergic stimulation in GSK3 inhibitor-treated cells, which also correlated with increased 
protein levels, however basal levels were not affected. We achieved an efficient siRNA-mediated GSK3 knockdown 
(Fig. 6d), and even though the effects of SB216763 on Fgf21, Dio2 and Ppargc1α were mimicked by the knockdown, 
the effect on Ucp1 was not. In addition, we observed that knockdown of GSK3 led to increased oxygen consumption 
following β-adrenergic stimulation (Fig. 3e,g), which might be a consequence of increased levels of Ppargc1a and Dio2 
(Fig. 3c) and thereby mitochondrial biogenesis and intracellular conversion of T4 to T3.
Because of its effect on a range of thermogenic genes, we hypothesised that GSK3 activity would impact a 
common regulatory pathway such as the MKK3/6-p38 MAPK-ATF2 module, which is well described as con-
trolling Fgf21, Ucp1 and Ppargc1α expression in brown adipocytes10,13–15. We found that inhibition of GSK3 
promoted activation of MKK3/6, p38 MAPK and ATF2, and that functional p38 MAPK signaling was necessary 
for the observed effects of a GSK3 inhibitor (Fig. 6). Therefore, our data suggest that GSK3 suppresses the signal 
upstream of MKK3/6. MKK3/6 is activated by members of the MAPK kinase kinase (MAP3K) family38. MAP3K 
involvement in controlling brown adipocyte gene expression is less well understood, however a few of the family 
members have been linked to specific functions in brown adipocytes. Recently, it was discovered that MAP3K5 
regulates brown and beige adipocyte function39 and a second MAP3K, MAP3K4, has previously been reported to 
enhance thermogenic gene expression in adipocytes through activated growth arrest and DNA-damage-inducible 
45γ in a PKA-dependent manner40. Interestingly, MAP3K4 contains several GSK3 consensus phosphorylation 
Figure 6. Inhibition of GSK3 promotes activation of the MKK3/6-p38 MAPK-ATF2 signaling module.  
(a) Immunoblot analysis for activating phosphorylations of proteins of the MKK3/6-p38 MAPK-ATF2 
signaling module in primary brown adipocytes pre-treated with 10 μM SB216763 for 1 h before stimulation 
with 0.1 μM ISO for 1 h. (b) Immunoblot analysis of total and phosphorylated p38 MAPK in immortalized 
brown adipocytes overexpressing GSK3β mutants or empty vector. Cells were treated with 0.1 μM ISO for 1 h. 
(c) Fgf21 expression in primary brown adipocytes pre-treated with 10 μM SB202190 (p38 MAPK inhibitor) for 
1 h before treatment with 10 μM SB216763 (GSK3 inhibitor) for 1 h, followed by stimulation with 0.1 μM ISO 
for additional 6 h. (d) Schematic presentation of the proposed mechanism through which GSK3 regulates the 
thermogenic gene program in brown adipocytes. Data presented as mean of means +SEM (n = 3). Statistical 
significance was determined by two-way ANOVA with repeated measures and Tukey’s post hoc test for multiple 
comparisons. *p < 0.05 versus H2O. #p < 0.05 versus vehicle. For panels a and b, full-length blots/gels are 
presented in Supplementary Fig. 2.
www.nature.com/scientificreports/
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sites and GSK3 has been identified as a negative regulator of MAP3K4 through binding to its kinase domain 
in COS cells and primary embryonic fibroblasts41. It is thus possible that GSK3 impacts the MKK3/6-p38 
MAPK-ATF2 module by negatively interfering with the activity of a specific MAP3K, such as MAP3K4, thereby 
restricting the entire signaling module.
Interestingly, only few negative regulators of the adipocyte thermogenic gene program have been identified, 
and most of these work by targeting PGC-1α stability or thermogenic genes directly by binding to promoter 
regions42. Here we have identified GSK3 as a novel negative regulator of the brown adipocyte thermogenic gene 
program, through active suppression of the PKA-dependent MKK3/6-p38 MAPK-ATF2 signaling module 
(Fig. 6d). For the upstream regulation of GSK3 activity, we show that following cold and β-adrenergic stim-
ulation, the thermogenic gene program in brown adipocytes is de-repressed through induction of inhibitory 
phosphorylations of GSK3 (Fig. 4b,c). Recently, similar findings on GSK3 phosphorylation were made in 3T3-L1 
cells after stimulation with ISO43. Moreover, two independent in vitro studies and one in vivo study, all in cardio-
myocytes, have shown that GSK3α and GSK3β become inactivated when treated with ISO44–46. Since PKA is the 
master regulator of brown adipocyte activity and thermogenic gene expression following cold or β-adrenergic 
stimulation30, we speculated that GSK3 inactivation might be downstream of PKA. Indeed, GSK3 inactivation 
was PKA-dependent in vitro and in vivo (Fig. 5b,c). However, one AdipoQ-caPKA mouse did not appear to exhibit 
increased PKA activity, as evident by lack of phosphorylation of HSL, and consistently displayed lower levels of 
phosphorylated GSK3 compared to the other AdipoQ-caPKA mice (Fig. 5c). In line with our results, it has pre-
viously been shown that PKA, upon stimulation of NIH-3T3 and HEK293 cells with ISO, can inactive GSK3α 
and GSK3β by phosphorylation at Ser21 and Ser9, respectively31. Similarly, it was recently shown that the GSK3 
interaction protein, GSKIP, facilitates the phosphorylation of GSK3 by PKA at Ser9 and Ser21 and thereby its 
inhibition in HEK293 cells47. Therefore, it seems likely that GSK3 inactivation following ISO stimulation of brown 
adipocytes is also a direct consequence of PKA phosphorylation. However, we cannot rule out that other GSK3 
kinases are responsible for the phosphorylation of Ser9 and Ser21. One such candidate kinase is AKT that is itself 
regulated by β-adrenergic receptor activation (Fig. 6a). Beside the inhibitory phosphorylation at Ser9/Ser21, an 
inhibitory phosphorylation at Ser389, carried out by p38 MAPK, has been detected on GSK3β in brain48. Thus, it 
is possible that GSK3β following cold and β-adrenergic stimulation could also be inhibited by p38 MAPK activity, 
downstream of PKA, adding a second layer of regulation to GSK3 activity in brown adipocytes.
Small-molecule inhibitors of GSK3 are already being considered for the treatment of Alzheimer’s disease, 
bipolar disorder, certain cancers and type 2 diabetes49,50. Interestingly, studies with rodent models of metabolic 
disease have demonstrated that inhibiting GSK3 has beneficial effects on systemic metabolism, but also impact 
whole-body non-specific metabolic actions. GSK3 inhibitors were found to ameliorate diet-induced obesity, 
decrease adiposity and hepatic steatosis and improve glucose tolerance and lipid profiles22–25. These effects have 
mainly been accredited to improved insulin signaling, preservation of β-cell function and increased glycogen 
deposition in the liver. To our knowledge, the direct effect of GSK3 inhibitors on adipose tissue has not been 
studied. Here we show using cultured mouse brown adipocytes that inhibiting GSK3 can increase thermogenic 
gene expression, energy expenditure and adipokine secretion. The effects of inhibiting GSK3 in adipose tissue of 
mice and in human brown adipocytes remain to be shown.
To harvest the metabolic benefits of BAT, finding negative regulators of thermogenic activation is of impor-
tance, since these regulators might be druggable targets. Here, we propose that GSK3 is such a druggable target 
that has the potential to allow a release of the brake on BAT activity to impact whole-body energy metabolism.
Methods
Mice. Mice used in Figs 1 and 4 were single-caged 10 weeks old male C57BL/6JBomTac mice (Taconic), 
housed at room temperature and fed standard chow diet. For cold experiments, mice were kept at 4 °C or 30 °C 
(thermoneutrality) for 4 days. Animals were killed by cervical dislocation, and iBAT, aBAT, iWAT, eWAT, heart, 
skeletal muscle and liver were rapidly excised and snap frozen in liquid nitrogen and stored at −80 °C. Blood 
was collected by sub-mandibular puncture and serum was prepared. Mouse experiments were preapproved and 
conducted in accordance with the legislation of Danish authorities. The AdipoQ-caPKA mice used in Fig. 5 have 
been described33, and were maintained according to a protocol approved by the Institutional Animal Care and 
Use Committee of the University of Chicago.
Cell culture. Brown pre-adipocytes immortalized with SV40 large T antigen were kindly provided by Dr. C. 
Ronald Kahn51. The cells were propagated in DMEM (Life Technologies) containing 10% fetal bovine serum (FBS) 
(Life Technologies). Two days post-confluence (designated day 0) differentiation was induced by addition of prop-
agation medium supplemented with 1 μM dexamethasone (Sigma-Aldrich), 0.5 mM isobutyl-1-methylxanthine 
(IBMX) (Sigma-Aldrich), 5 μg/ml insulin (Roche) and 0.5 μM rosiglitazone (Cayman Chemical). At day 2, the 
medium was changed to medium containing 5 μg/ml insulin and 0.5 μM rosiglitazone. From day 4, cells were 
cultured in propagation medium and the cells were considered mature at day 8. The cells were kept at 37 °C in 
a humidified atmosphere with 5% CO2. 3T3-L1, C2C12 and hMADS cells were kindly provided by Dr. Karsten 
Kristiansen (3T3-L1, C2C12) and Dr. Christian Dani (hMADS)52. 3T3-L1 and hMADS cells were propagated and 
differentiated as described53. C2C12, HepG2 (ATCC) and Hepa1-6 (ATCC) cells were propagated in the same 
medium as the immortalized brown pre-adipocytes. Differentiation of C2C12 cells was induced by replacing the 
propagation medium with DMEM containing 2% horse serum from two days post-confluence (designated day 0 
and considered as myoblasts). The cells were considered mature myocytes at day 2. HepG2 and Hepa1-6 cells were 
harvested at 80% confluence. Primary CD-1 mouse hepatocytes were obtained from Life Technologies (MSCP10) 
and were propagated according to the manufacturer’s instructions. All media contained 62.5 μg/ml penicillin and 
100 μg/ml streptomycin (Sigma-Aldrich).
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Isolation and culture of primary brown adipocytes. Isolation and culture of primary brown 
pre-adipocytes from male 3–4 weeks old NMRI mice (Taconic) were done as described53, except that the cell 
culture medium was changed at days 1, 4, 6 and 8 after isolation.
Gene expression. Isolation of total RNA, reverse transcription and RT-qPCR was done as described54, except 
that the SensiFAST SYBR Lo-ROX Kit was used. Primers used were: Tbp, fwd-ACCCTTCACCAATGACTCCTATG, 
rev-ATGATGACTGCAGCAAATCGC; Ucp1, fwd-AGCCGGCTTAATGACTGGAG, rev-TCTG TAGGCTGCCC 
AATGAAC; Fgf21, fwd-AGATGGAGCTCTCTATGGATCG, rev-GGGCTTCAGACTGGTACACAT; Fabp4, fwd- 
TGGAAGCTTGTCTCCAGTGA, rev-AATCCCCATTTACGCTGATG; AdipoQ, fwd-AACTTGTGCAGGTTGGA 
TGGC, rev-TTCTCTCCCTTCTCTCCAGGA; Cebpa, fwd-TGGACAAGAACAGCAACGAG, rev-TCACTGGTCA 
ACTCCAGCAC; Dio2, fwd-CAGTGTGGTGCACGTCTCCAATC, rev-TGAACCAAAGTTGACCACCAG; 
Ppargc1a, fwd-AGCCGTGACCACTGACAACGAG, rev-GCTGCATGGTTCTGAGTGCTAAG.
FGF21 secretion measurements. FGF21 levels in plasma and cell culture medium were determined with 
the Mouse/Rat FGF-21 Quantikine ELISA Kit (R&D Systems) according to the instructions of the manufacturer.
Kinase inhibitors and activators. The Tocriscreen Kinase Inhibitor Toolbox containing 80 kinase inhib-
itors was supplemented with 10 additional inhibitors (Tocris Bioscience)28. SB415286, SB216763, BIO, H89 and 
SB202190 were obtained from Tocris Bioscience. 6-MB-cAMP was from Biolog. All compounds were dissolved 
in DMSO, except for 6-MB-cAMP which was dissolved in water.
Immunoblotting. Preparation of whole-cell extracts and immunoblotting were carried out essentially as 
described55. Briefly, protein lysates were separated using NuPage 4–12% Bis-Tris gradient gels (Life Technologies) 
and transferred by semi-dry blotting onto polyvinylidene difluoride membrane (GE Healthcare). Equal loading 
was confirmed by Amido Black staining (Sigma-Aldrich). All washing and incubation steps were carried out with 
Tris-buffered saline containing 0.1% Tween-20 and 5% non-fat dry milk or BSA. Primary antibodies used were: 
CREB (#9192), p-CREB (Ser133) (#9198), GSK3α (#4337), p-GSK3α (Ser21) (#9316), GSK3β (#12456), p-GSK3β 
(Ser9) (#5558), p38 MAPK (#9212), p-p38 MAPK (Thr180/Tyr182) (#9211), MKK3 (#8535), MKK6 (#8550), 
p-MKK3/6 (Ser189/Ser207) (#12280), ATF2 (#9226), p-ATF2 (Thr71) (#5112), HSL (#4107), p-HSL (Ser660) 
(#4126), Phospho-(Ser/Thr) PKA substrate (#9621) (all from Cell Signaling Technology), TFIIB (#sc-225) (Santa 
Cruz Biotechnology), Vinculin (#V9264) (Sigma-Aldrich), UCP1 (#10983) (Abcam) and HA (#11583816001) 
(Roche). Secondary antibodies were horseradish peroxidase-conjugated anti-rabbit or anti-mouse (DAKO). 
EZ-ECL Enhanced Chemiluminescence Detection Kit for HRP (Biological Industries) was used for detection.
Retroviral overexpression. Human pcDNA3-HA-GSK3β-S9A and human pcDNA3-HA-GSK3β-K85A 
were a gift from Jim Woodgett (Addgene plasmid number #14755 and #14754). GSK3β fragments were 
inserted into the EcoRI/ApaI site of pMSCVneo link354 to create pMSCVneo-HA-GSK3β-S9A and 
pMSCVneo-HA-GSK3β-K85A. Phoenix-Eco cells were transfected with retroviral vectors at 50–60% confluence 
using Fugene HD Transfection Reagent (Promega). 48 and 72h after transfection, the virus-containing super-
natant was harvested and filtered. Subconfluent immortalized brown preadipocytes were transduced with the 
virus-containing supernatant diluted with DMEM containing 10% FBS and supplemented with 4.5 μg/ml poly-
brene (Sigma-Aldrich). Transduced cells were selected with 400 μg/ml G418 (Sigma-Aldrich).
Reverse siRNA transfection. Reverse siRNA transfections were performed as described53. siRNAs used 
were GSK3α (SASI_Mm01_00126759) and GSK3β (SASI_Mm01_00141911) (Sigma-Aldrich). The MISSION® 
siRNA Universal Negative Control #1 (Sigma-Aldrich, SIC001) was used as control siRNA.
Oxygen consumption measurements. Real-time measurements of oxygen consumption rate (OCR) 
were performed using a Seahorse XF96 Extracellular Flux Analyzer (Agilent Technologies). Mature primary 
brown adipocytes were replated from 6-well plates at day 8 after isolation and reverse transfected in 96-well XF 
Cell Culture Microplates (Agilent Technologies) as previously described53. Cells were kept in growth medium 
until the day of the experiment, i.e. 4 days after transfection. The cell culture medium was changed 1 h before the 
first measurement to DMEM (without serum) supplemented with 5 mM glucose and adjusted to pH 7.4. OCR 
was measured under basal conditions and following isoproterenol injection.
Glycerol release. Glycerol release into the cell culture medium was measured with the Adipolysis Assay Kit 
(Cayman Chemical) following the instructions of the manufacturer.
Statistics. All statistical tests of gene expression were performed on log-transformed data. Unpaired 
two-tailed Student’s t-test was used for single comparisons. Two-way ANOVA with repeated measures and 
Tukey’s post hoc test was used for multiple comparisons.
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